Catalog No.: PC-63323Not For Human Use, Lab Use Only.
AB-423 is a novel potent, class II HBV capsid inhibitor that shows potent inhibition of HBV replication with EC50 of 0.08-0.27 uM, with no significant cytotoxicity (CC50>10 uM).
AB-423 (AB423) is a potent, class II HBV capsid inhibitor that shows potent inhibition of HBV replication with EC50 of 0.08-0.27 uM, with no significant cytotoxicity (CC50>10 uM).
AB-423 inhibits HBV genotypes A through D and nucleos/tide-resistant variants, causes capsid particles devoid of encapsidated pgRNA and rcDNA in treated HepDES19 cells.
AB-423 prevents the conversion of encapsidated rcDNA to cccDNA presumably by interfering with the capsid uncoating process.
AB-423 dose-dependently reduces serum HBV DNA levels in mouse model of HBV model, shows synergistic antiviral activity combined with entecavir (ETV).
